Supportive Care

SUPPORTIVE CARE NEWS & FEATURES

Potential Unintended Consequences of the “Right to Try” Act on the Delivery of Palliative Care to Children With Cancer

Will “cure-seeking behavior” for terminally ill children with cancer interfere with the integrated delivery of palliative care?

Opioid Equianalgesic Doses

Opioid equianalgesic dosing chart used for interchanging between drug, route of administration, or both.

Chemobrain: Experts Weigh in on Very Real — and Growing — Problem

Major advances in cancer treatment in recent decades have allowed patient survival rates to increase.

Additional Method of Administration Approved for Cinvanti in Chemotherapy-Induced Nausea and Vomiting

Heron Therapeutics announced that the Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for Cinvanti (aprepitant) to expand administration to include a 2-minute intravenous (IV) injection, in addition to the already approved 30-minute IV infusion.

Guideline Updates on Quality Palliative Care

A draft guideline from the National Consensus Project for Quality Palliative Care describes best practices for caring for individuals who are seriously ill.

Commission Calls for Integration of Oncology and Palliative Care

A recent Lancet Oncology Commission laid out why oncology and palliative care should be integrated and how to achieve successful integration despite barriers.

Managing Chemotherapy- and Radiation Therapy-Induced Nausea and Vomiting

CINV and RINV are a frequent source of misery and distress for patients and ineffective emesis control has well-documented impacts on health-related quality of life.

Oral Mucositis: Chemotherapy-Associated Toxicity

Patients who receive chemotherapy or radiation therapy are at risk for developing oral mucositis, which causes inflammatory and/or ulcerative lesions of the oral mucosa

Non-Drug Costs of CAR-T Cell Therapy May Exceed $50,000

Researchers noted that while non-drug costs account for only 7% of CAR-T therapy-related expenses, these costs may range from $30,000 to $56,000.

Late-Onset Toxicity Possible With Immunotherapy

Postapproval studies are needed to further characterize the risk and long-term safety of immune checkpoint inhibition.